PATENT CLAIM ANALYSIS

Application Number: 15759305
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "04400A"]

Abstract:
There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level. The present invention provides a specific antisense oligomer which allows exon 2 skipping in the myostatin gene or induces degradation of mRNA of the myostatin gene.

Claim (Index 18):
A method for prevention or treatment of an amyotrophic disease or a muscle wasting disease, which comprises administering a subject in need of prevention or treatment of an amyotrophic disease or a muscle wasting disease with a therapeutically effective amount of the antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to  claim 1 .

Metadata:
- Claim Count in Document: 8.0
- Percentile: 90.0
- Lexical Diversity: 1.38889
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15759267', '15314535', '14368307', '15122435', '15339069']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8297914321151109
- 35 USC 102 Novelty (BERT): 0.570368183460655
- Combined Prediction Score: 0.8038491072496652
- Mean Citation Score: 427.308318
- Max Citation Score: 475.8151
- Similarity Product: 379.9447959299922

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test